Clinical Trial Update: A Phase I Trial of QLS2313 Injection in Relapsed/Refractory Hematological Malignancies [Phase 1]

View source ↗

Summary

A Phase I clinical trial of QLS2313 injection in patients with relapsed or refractory hematologic malignancies, currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• QLS2313

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Relapsed/Refractory Hematological Malignancies | Phase 1 | Status: NOT_YET_RECRUITING